Skip to main content
. 2020 Aug 12;8:724. doi: 10.3389/fcell.2020.00724

FIGURE 7.

FIGURE 7

Promoter hypomethylation was responsible for HDAC11 overexpression in HCC. (A,B) HDAC11 was upregulated, whereas its promoter methylation level was downregulated in all HCC samples compared with normal controls. (C,D) HDAC11 was upregulated, whereas its promoter methylation level was downregulated in HCC based on tumor grade. (E,F) HDAC11 was upregulated, whereas its promoter methylation level was downregulated in HCC based on individual cancer stages. (G,H) HDAC11 was upregulated, whereas its promoter methylation level was downregulated in HCC based on nodal metastasis status. (I) The expression of HDAC11 was significantly increased after treatment of DNA methyltransferase inhibitor 5’-Aza-2’-deoxycytidine in SMMC7721. (J) The expression of HDAC11 was significantly increased after treatment of DNA methyltransferase inhibitor 5’-Aza-2’-deoxycytidine in SMMC7721/SR. (K) The expression of HDAC11 was significantly increased after treatment of DNA methyltransferase inhibitor 5’-Aza-2’-deoxycytidine in MHCC97L. (L) The expression of HDAC11 was significantly increased after treatment of DNA methyltransferase inhibitor 5’-Aza-2’-deoxycytidine in MHCC97H. *P < 0.05, **P < 0.01, ***P < 0.001.